Please ensure Javascript is enabled for purposes of website accessibility

Rite Aid Is More Than Just a Turnaround Story Now

By Philip Saglimbeni - Apr 11, 2014 at 12:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

While many investors are still trying to figure out whether or not Rite Aid is turning around, the company is displaying solid growth on the heels of an aggressive expansion strategy.

After significant doubt on my part, I finally have to admit that the turnaround happening at Rite Aid (RAD 7.95%) appears to be real. In fact, the turnaround may be much more than real; it may even be worth investing in.

Rite Aid recently announced its fourth-quarter earnings. The results were mostly impressive, beating consensus estimates on both the top and bottom lines. Additionally, the company announced that it was acquiring a RediClinic, a leading operator of retail clinics in America. The news was enough to send shares of Rite Aid soaring more than 14% at the open.

Source: Rite Aid

Earnings beat
For the fourth quarter of fiscal 2014, Rite Aid reported revenue of $6.6 billion and earnings of $0.06 per diluted share. Results handily beat the average analyst estimates of $6.54 billion and $0.04 per share, respectively.

On a year-over-year basis, fourth-quarter revenue grew 2.2% from $6.5 billion. The top line was driven in large part by strength in comparable-pharmacy-store sales, which grew 3.5% in the quarter. Excluding outside items, diluted earnings per share would have been $0.10 for the quarter, representing a nice improvement from last year's EPS of $0.07.

In the company's press release, Rite Aid Chairman and Chief Executive Officer John Standley stated,

Thanks to the strong teamwork of our dedicated Rite Aid associates, we delivered strong fourth-quarter and fiscal 2014 results, including new company records for fourth-quarter and full-year [a]djusted [earnings before interest, taxes, depreciation, and amortization].

Standley added:

These accomplishments reflect the significant progress we're making in executing key initiatives and delivering on our promise to actively work with our customers to keep them well.

From turnaround to growth
In the earnings release, management reiterated the news that longtime Rite Aid shareholders have been waiting so long to hear: The company has progressed from being a turnaround story to a growth story.

The fundamental change in story at Rite Aid has been driven by several initiatives: management's focus on acquiring strong brands like RediClinic to strengthen the company's overall health-care portfolio, the expansion of its existing deal with McKesson Corporation (MKC 2.74%), and the further build out and remodeling process of store locations.

The acquisition of RediClinic, of which terms were not disclosed, represents a significant step for Rite Aid. The move will not only help the company expand into the greater Texas area, where RediClinic is based, but it will also allow the pharmacy company to expand into the retail-clinic space.

CEO Standley said:

Retail clinics play a critical role in today's health care delivery system and will play an important role in Rite Aid's overall health and wellness strategy. We are committed to working with RediClinic to expand its current footprint in Texas and, in the near future, begin to bring its expertise in delivering convenient health care and wellness programs to Rite Aid customers in select Rite Aid markets.

The expanded agreement with McKesson is significant as well. As a leader in pharmaceutical sourcing and supply management, McKesson is a major component of Rite Aid's pharmacy business. The company is responsible for sourcing and distributing the pharmacy's generic drugs, which means Rite Aid and its customers can take advantage of McKesson's direct-to-store delivery method for generic and branded medicine.

The current deal in place between the two companies was set to expire in March 2016 but has since been extended to March 2019.

Finally, in the last year alone, Rite Aid remodeled 405 of its store locations, relocated another 11, expanded five, and acquired one. The best part is that management has stated numerous times that store expansion will remain a priority for Rite Aid in the years ahead.

Bottom line
As one of the relatively smaller national pharmacy chains right now, Rite Aid is making big moves. The company successfully turned around its challenged business in the last few years and returned to growth.

The fact that management is keeping its foot on the throttle, as evidenced by the recent acquisition of RediClinic, should be extremely encouraging to investors. The market must now view Rite Aid as less of a turnaround play and more of a growth story in the health-care industry.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Rite Aid Corporation Stock Quote
Rite Aid Corporation
$8.69 (7.95%) $0.64
McCormick & Company, Incorporated Stock Quote
McCormick & Company, Incorporated
$87.84 (2.74%) $2.34

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.